Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | GPR4 | P46093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22906696 | 1.00 | SPHK1 (0.44) | SPHK1CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL26044480 | 0.88 | CYP4F2 (0.42) | SPHK1CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL19008242 | 0.87 | USP2 (0.42) | SPHK1USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL2954455 | 0.84 | CYP4F2 (0.43) | SPHK1CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL2286177 | 0.84 | USP2 (0.44) | SPHK1USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL4836593 | 0.84 | GPR4 (0.45) | SPHK1CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL18497595 | 0.81 | USP2 (0.36) | SPHK1CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL571327 | 0.81 | NR1H2 (0.44) | CYP4F2CYP4A11USP2SMN1; SMN2NR1H2 | |
| SCHEMBL22233695 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2NR1H2HPGD | |
| SCHEMBL597478 | 0.79 | GPR4 (0.46) | CYP4F2CYP4A11USP2SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | SPHK1 4614/4885CYP4F2 4477/4885CYP4A11 4517/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | SPHK1 4693/4885CYP4F2 4640/4885CYP4A11 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.